<!DOCTYPE html>
<html lang="en">

<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Lesson 16.4: Hormonal Complexity: Estrogen Dominance, PCOS, and Phase II Detoxification</title>
    <style>
        /* Base & Reset */
        * {
            box-sizing: border-box;
        }

        body {
            font-family: Georgia, 'Times New Roman', serif;
            line-height: 1.8;
            color: #2d2d2d;
            background: #f8f6f3;
            margin: 0;
            padding: 0;
        }

        /* Main Container */
        .lesson-container {
            max-width: 860px;
            margin: 0 auto;
            padding: 40px 30px;
            background: #ffffff;
            min-height: 100vh;
            box-shadow: 0 0 60px rgba(0, 0, 0, 0.08);
        }

        /* Brand Header */
        .brand-header {
            text-align: center;
            padding-bottom: 30px;
            margin-bottom: 35px;
            border-bottom: 1px solid #eee;
        }

        .brand-logo {
            max-width: 220px;
            height: auto;
            margin-bottom: 5px;
        }

        /* Module Header - PURPLE/GOLD theme for Advanced Endocrine */
        .module-header {
            background: linear-gradient(135deg, #4c1d95 0%, #6d28d9 100%);
            padding: 35px 35px 30px;
            border-radius: 16px;
            margin-bottom: 30px;
            position: relative;
            overflow: hidden;
        }

        .module-header::before {
            content: '';
            position: absolute;
            top: 0;
            right: 0;
            width: 300px;
            height: 300px;
            background: radial-gradient(circle, rgba(255, 255, 255, 0.1) 0%, transparent 70%);
            transform: translate(100px, -100px);
        }

        .module-header::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 100%;
            height: 4px;
            background: linear-gradient(90deg, #B8860B, #D4A84B, #B8860B);
        }

        .module-label {
            margin: 0;
            font-size: 11px;
            color: rgba(255, 255, 255, 0.75);
            text-transform: uppercase;
            letter-spacing: 2.5px;
            font-weight: 500;
        }

        .lesson-title {
            margin: 10px 0 0 0;
            font-size: 28px;
            color: #ffffff;
            font-weight: 700;
            line-height: 1.3;
            position: relative;
        }

        .lesson-meta {
            display: flex;
            gap: 12px;
            margin-top: 20px;
            padding-top: 18px;
            border-top: 1px solid rgba(255, 255, 255, 0.15);
            flex-wrap: wrap;
        }

        .meta-item {
            display: flex;
            align-items: center;
            gap: 6px;
            font-size: 12px;
            color: rgba(255, 255, 255, 0.85);
            background: rgba(255, 255, 255, 0.1);
            padding: 5px 12px;
            border-radius: 4px;
        }

        /* Table of Contents */
        .toc-box {
            background: linear-gradient(135deg, #fafafa 0%, #f5f5f5 100%);
            border-radius: 14px;
            padding: 24px 28px;
            margin-bottom: 35px;
            border: 1px solid #e8e8e8;
        }

        .toc-box .box-label {
            font-weight: 600;
            color: #4c1d95;
            margin: 0 0 18px 0;
            font-size: 12px;
            text-transform: uppercase;
            letter-spacing: 2px;
            padding-bottom: 12px;
            border-bottom: 1px solid #e0e0e0;
        }

        .toc-list {
            list-style: none;
            margin: 0;
            padding: 0;
            display: grid;
            grid-template-columns: repeat(2, 1fr);
            gap: 8px 24px;
        }

        .toc-list li {
            margin: 0;
        }

        .toc-list a {
            display: flex;
            align-items: center;
            padding: 8px 12px;
            color: #555;
            text-decoration: none;
            font-size: 14px;
            border-radius: 6px;
            transition: all 0.2s ease;
        }

        .toc-list a:hover {
            background: white;
            color: #4c1d95;
            box-shadow: 0 2px 8px rgba(0, 0, 0, 0.06);
        }

        .toc-list .section-num {
            display: inline-flex;
            align-items: center;
            justify-content: center;
            width: 26px;
            height: 26px;
            background: #4c1d95;
            color: white;
            font-weight: 600;
            font-size: 11px;
            border-radius: 6px;
            margin-right: 12px;
            flex-shrink: 0;
        }

        /* Learning Objectives */
        .objectives-box {
            background: #f5f3ff;
            border: 2px solid #6d28d9;
            border-radius: 14px;
            padding: 30px 35px;
            margin-bottom: 40px;
        }

        .objectives-box .box-label {
            font-weight: 600;
            color: #4c1d95;
            margin: 0 0 18px 0;
            font-size: 13px;
            text-transform: uppercase;
            letter-spacing: 2px;
            display: flex;
            align-items: center;
            gap: 10px;
        }

        .objectives-box .box-label::before {
            content: 'üéØ';
            font-size: 18px;
        }

        .objectives-box ul {
            margin: 0;
            padding-left: 22px;
        }

        .objectives-box li {
            margin-bottom: 14px;
            font-size: 16px;
            line-height: 1.7;
        }

        /* Section Headings */
        h2 {
            font-size: 24px;
            color: #4c1d95;
            margin: 50px 0 20px 0;
            font-weight: 600;
            position: relative;
            padding-bottom: 12px;
        }

        h2::after {
            content: '';
            position: absolute;
            bottom: 0;
            left: 0;
            width: 60px;
            height: 3px;
            background: #B8860B;
        }

        h3 {
            font-size: 20px;
            color: #1e1b4b;
            margin: 30px 0 15px 0;
        }

        /* Paragraphs & Highlighting */
        p {
            font-size: 17px;
            margin-bottom: 20px;
            color: #333;
        }

        .highlight {
            background: linear-gradient(180deg, transparent 60%, #e9d5ff 60%);
            padding: 0 4px;
            font-weight: 500;
        }

        .stat-highlight {
            color: #4c1d95;
            font-weight: 700;
        }

        /* Case Study Box */
        .case-study {
            background: linear-gradient(135deg, #f8f9fb 0%, #f0f2f5 100%);
            border-radius: 16px;
            padding: 0;
            margin: 40px 0;
            overflow: hidden;
            box-shadow: 0 4px 20px rgba(0, 0, 0, 0.06);
        }

        .case-study-header {
            background: linear-gradient(135deg, #4c1d95 0%, #6d28d9 100%);
            padding: 20px 30px;
            display: flex;
            align-items: center;
            gap: 15px;
        }

        .case-study-icon {
            width: 45px;
            height: 45px;
            background: rgba(255, 255, 255, 0.15);
            border-radius: 10px;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 22px;
        }

        .case-study-header .box-label {
            font-weight: 600;
            color: #ffffff;
            margin: 0;
            font-size: 16px;
        }

        .case-study-content {
            padding: 28px 30px;
        }

        .patient-profile {
            display: flex;
            align-items: center;
            gap: 18px;
            padding: 18px 22px;
            background: white;
            border-radius: 12px;
            margin-bottom: 20px;
            border: 1px solid #e5e5e5;
        }

        .patient-avatar {
            width: 55px;
            height: 55px;
            background: linear-gradient(135deg, #6d28d9, #4c1d95);
            border-radius: 50%;
            display: flex;
            align-items: center;
            justify-content: center;
            font-size: 24px;
            color: white;
        }

        /* Data Tables */
        .data-table-container {
            margin: 30px 0;
            overflow-x: auto;
            border-radius: 12px;
            border: 1px solid #e5e7eb;
        }

        table {
            width: 100%;
            border-collapse: collapse;
            font-size: 15px;
        }

        th {
            background: #f9fafb;
            padding: 15px;
            text-align: left;
            font-weight: 600;
            color: #4c1d95;
            border-bottom: 2px solid #e5e7eb;
        }

        td {
            padding: 15px;
            border-bottom: 1px solid #e5e7eb;
            vertical-align: top;
        }

        /* Statistics Box */
        .stats-box {
            background: linear-gradient(135deg, #4c1d95 0%, #6d28d9 100%);
            padding: 35px;
            border-radius: 16px;
            margin: 35px 0;
            color: white;
        }

        .stats-grid {
            display: grid;
            grid-template-columns: repeat(auto-fit, minmax(180px, 1fr));
            gap: 25px;
        }

        .stat-item {
            text-align: center;
        }

        .stat-number {
            font-size: 36px;
            font-weight: 700;
            display: block;
        }

        .stat-label {
            font-size: 12px;
            text-transform: uppercase;
            letter-spacing: 1px;
            opacity: 0.9;
        }

        /* Check Understanding */
        .check-understanding {
            background: #fdfbf7;
            border: 2px solid #B8860B;
            border-radius: 16px;
            padding: 32px;
            margin: 45px 0;
        }

        .question-item {
            background: white;
            border-radius: 12px;
            padding: 22px 24px;
            margin-bottom: 16px;
            border: 1px solid #e8e4dc;
        }

        .reveal-btn {
            background: #4c1d95;
            color: white;
            border: none;
            padding: 10px 20px;
            border-radius: 8px;
            cursor: pointer;
            font-family: inherit;
        }

        .answer-text {
            display: none;
            margin-top: 15px;
            padding: 15px;
            background: #f3f4f6;
            border-radius: 8px;
            font-style: italic;
        }

        .answer-text.show {
            display: block;
        }

        /* Takeaways & References */
        .takeaways-box {
            background: #f9fafb;
            padding: 25px;
            border-radius: 12px;
            border-left: 5px solid #4c1d95;
            margin: 40px 0;
        }

        .references-box {
            background: #ffffff;
            padding: 25px;
            border-radius: 12px;
            border: 1px solid #eee;
            margin-top: 40px;
            font-size: 14px;
        }

        .references-box h4 {
            margin-top: 0;
            color: #666;
            text-transform: uppercase;
            font-size: 12px;
            letter-spacing: 1px;
        }

        .lesson-footer {
            text-align: center;
            padding: 40px 0;
            border-top: 1px solid #eee;
        }

        @media (max-width: 768px) {
            .toc-list { grid-template-columns: 1fr; }
            .lesson-container { padding: 20px 15px; }
        }
    </style>
</head>

<body>
    <div class="lesson-container">
        <div class="brand-header">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="brand-logo">
        </div>

        <header class="module-header">
            <p class="module-label">Module 16: Advanced Case Studies</p>
            <h1 class="lesson-title">Lesson 4: Hormonal Complexity: Estrogen Dominance, PCOS, and Phase II Detoxification</h1>
            <div class="lesson-meta">
                <span class="meta-item">‚è± 35 min read</span>
                <span class="meta-item">üéì Advanced Level</span>
            </div>
        </header>

        <div class="toc-box">
            <p class="box-label">In This Lesson</p>
            <ul class="toc-list">
                <li><a href="#section1"><span class="section-num">1</span> The PCOS-Estrogen Paradox</a></li>
                <li><a href="#section2"><span class="section-num">2</span> Phase I & II Detoxification Pathways</a></li>
                <li><a href="#section3"><span class="section-num">3</span> The Estrobolome & Beta-Glucuronidase</a></li>
                <li><a href="#section4"><span class="section-num">4</span> Genetic Drivers: COMT & MTHFR</a></li>
                <li><a href="#section5"><span class="section-num">5</span> Case Study: Elena's PCOS Journey</a></li>
                <li><a href="#section6"><span class="section-num">6</span> The Blended Protocol & Cycle Syncing</a></li>
            </ul>
        </div>

        <div class="objectives-box">
            <p class="box-label">Learning Objectives</p>
            <ul>
                <li>Deconstruct the relationship between hyperandrogenism and impaired estrogen clearance.</li>
                <li>Identify the clinical significance of COMT and MTHFR polymorphisms in hormone metabolism.</li>
                <li>Master the use of DIM and Calcium D-Glucarate in modulating Phase I and II detoxification.</li>
                <li>Implement "Data-Driven Decisions" using the DUTCH test and genomic analysis.</li>
                <li>Apply cycle-syncing nutritional protocols to optimize the B.R.I.D.G.E. Method‚Ñ¢ framework.</li>
            </ul>
        </div>

        <h2 id="section1">1. The PCOS-Estrogen Paradox</h2>
        <p>In conventional endocrinology, <span class="highlight">Polycystic Ovary Syndrome (PCOS)</span> is often viewed through the narrow lens of androgen excess. However, as integrative practitioners, we must recognize that many PCOS phenotypes coexist with relative <span class="highlight">estrogen dominance</span>. This occurs not necessarily because of high absolute estrogen, but because of a failure in detoxification and an imbalance relative to progesterone.</p>

        <div class="stats-box">
            <div class="stats-grid">
                <div class="stat-item">
                    <span class="stat-number">1 in 10</span>
                    <span class="stat-label">Women affected by PCOS</span>
                </div>
                <div class="stat-item">
                    <span class="stat-number">70%</span>
                    <span class="stat-label">Remain Undiagnosed Globally</span>
                </div>
                <div class="stat-item">
                    <span class="stat-number">3.2x</span>
                    <span class="stat-label">Risk of Metabolic Syndrome</span>
                </div>
            </div>
        </div>

        <p>A 2022 meta-analysis published in <i>The Lancet Diabetes & Endocrinology</i> highlighted that while 80% of PCOS cases involve insulin resistance, the <span class="highlight">Estrobolome</span>‚Äîthe collection of gut bacteria capable of metabolizing estrogen‚Äîis often severely disrupted, leading to the recirculation of toxic estrogen metabolites. This recirculation exacerbates the inflammatory state, further driving the "Root Cause" of insulin resistance and androgen production in the theca cells.</p>

        <h2 id="section2">2. Phase I & II Detoxification Pathways</h2>
        <p>To address hormonal complexity, we must understand the hepatic "assembly line." Estrogen (estradiol/estrone) must be converted into water-soluble metabolites for excretion. This happens in two primary phases:</p>

        <h3>Phase I: Functionalization (CYP450 Enzymes)</h3>
        <p>Phase I converts estrogens into three metabolites via the P450 pathway:</p>
        <ul>
            <li><strong>2-OH (2-Hydroxyestrone):</strong> The "protective" pathway. Low risk for DNA damage.</li>
            <li><strong>4-OH (4-Hydroxyestrone):</strong> The "pro-carcinogenic" pathway. Can form quinones that damage DNA.</li>
            <li><strong>16-OH (16-alpha-Hydroxyestrone):</strong> The "proliferative" pathway. Associated with heavy bleeding and tissue growth.</li>
        </ul>

        <h3>Phase II: Conjugation (Methylation & Glucuronidation)</h3>
        <p>This is where many PCOS patients plateau. Even if Phase I is balanced, <span class="highlight">Phase II must neutralize</span> these metabolites. The most critical processes here are <strong>Methylation</strong> (via the COMT enzyme) and <strong>Glucuronidation</strong>.</p>

        <div class="data-table-container">
            <table>
                <thead>
                    <tr>
                        <th>Intervention</th>
                        <th>Mechanism of Action</th>
                        <th>Target Pathway</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>DIM (Diindolylmethane)</strong></td>
                        <td>Shifts CYP1A1 activity to favor 2-OH over 4-OH/16-OH.</td>
                        <td>Phase I Detox</td>
                    </tr>
                    <tr>
                        <td><strong>Calcium D-Glucarate</strong></td>
                        <td>Inhibits beta-glucuronidase, preventing estrogen de-conjugation.</td>
                        <td>Phase III (Gut)</td>
                    </tr>
                    <tr>
                        <td><strong>S-Adenosylmethionine (SAMe)</strong></td>
                        <td>Provides methyl donors for the COMT enzyme.</td>
                        <td>Phase II (Methylation)</td>
                    </tr>
                    <tr>
                        <td><strong>Myo-inositol</strong></td>
                        <td>Improves insulin sensitivity and FSH signaling.</td>
                        <td>Root Cause (Insulin)</td>
                    </tr>
                </tbody>
            </table>
        </div>

        <h2 id="section3">3. The Estrobolome & Beta-Glucuronidase</h2>
        <p>The "E" in our B.R.I.D.G.E. Method‚Ñ¢ often involves <i>Evolving</i> the protocol to include the gut. The <span class="highlight">Estrobolome</span> produces an enzyme called <span class="highlight">beta-glucuronidase</span>. When this enzyme is too high (often due to dysbiosis), it "un-zips" the estrogen that the liver just spent energy packaging for excretion. This "liberated" estrogen is reabsorbed into the bloodstream, creating a vicious cycle of dominance.</p>

        <p>Research indicates that specific probiotic strains, particularly <i>Lactobacillus acidophilus</i> and <i>Bifidobacterium lactis</i>, can modulate beta-glucuronidase activity, while high-fiber interventions (35g+ daily) provide the physical matrix to bind these estrogens in the stool.</p>

        <h2 id="section4">4. Genetic Drivers: COMT & MTHFR</h2>
        <p>Using <strong>Data-Driven Decisions</strong> (Module 4), we look at Single Nucleotide Polymorphisms (SNPs). The <strong>COMT (Catechol-O-Methyltransferase)</strong> gene is responsible for methylating catechol estrogens (the 2-OH and 4-OH varieties). </p>
        
        <p>Individuals with the <span class="highlight">COMT Val158Met "Slow" variant</span> (AA genotype) have a 75% reduction in enzyme activity. For these patients, even "normal" estrogen levels can feel like dominance because they cannot clear the metabolites efficiently. When paired with an <strong>MTHFR</strong> mutation (limiting methyl donor availability), the hormonal system becomes a bottlenecked highway.</p>

        <div class="case-study">
            <div class="case-study-header">
                <div class="case-study-icon">üë©‚Äç‚öïÔ∏è</div>
                <div>
                    <p class="box-label">Case Study 16.4A: Elena's Refractory PCOS</p>
                    <p style="margin:0; font-size:12px; opacity:0.8;">Complex Hormonal & Genetic Integration</p>
                </div>
            </div>
            <div class="case-study-content">
                <div class="patient-profile">
                    <div class="patient-avatar">E</div>
                    <div class="patient-info">
                        <h4>Elena, 29 Years Old</h4>
                        <p>Presentation: PCOS, Hirsutism, 45-day cycles, severe PMS, and cystic acne.</p>
                    </div>
                </div>
                <p><strong>The Challenge:</strong> Elena had been on Metformin (1500mg) for two years. While her fasting glucose improved, her cycles remained irregular and her PMS "mood swings" were debilitating. Conventional labs showed high Testosterone (72 ng/dL) but "normal" Estradiol.</p>
                
                <p><strong>Integrative Assessment (B.R.I.D.G.E. Method):</strong></p>
                <ul>
                    <li><strong>Data:</strong> DUTCH test revealed very low 2-OH:16-OH ratio and poor methylation activity. Genomic testing confirmed COMT (Met/Met) and MTHFR (C677T) homozygous mutations.</li>
                    <li><strong>Root Cause:</strong> Impaired Phase II detoxification and elevated beta-glucuronidase (confirmed via GI-MAP).</li>
                </ul>

                <p><strong>Intervention:</strong> We added <span class="highlight">Calcium D-Glucarate (500mg BID)</span> and <span class="highlight">DIM (150mg)</span> to fix the clearance issue. We introduced 5-MTHF to support the methylation bottleneck. Finally, we synchronized her diet: high cruciferous vegetables in the follicular phase and seed cycling.</p>

                <p><strong>Outcome:</strong> Within 3 cycles, Elena's cycle length stabilized to 30 days. Her acne cleared by 80%, and the "brain fog" associated with her PMS vanished. Repeat DUTCH testing showed a 40% improvement in methylation index.</p>
            </div>
        </div>

        <h2 id="section5">5. The Blended Protocol</h2>
        <p>A "Premium" integrative approach doesn't always mean "all-natural." It means <span class="highlight">Blending Approaches</span> (Module 1). In cases of PCOS with significant insulin resistance, Metformin remains a gold-standard tool. However, Metformin can deplete Vitamin B12, which is essential for the very methylation pathways (COMT) we are trying to support.</p>

        <p><strong>The Synergy:</strong>
        <ul>
            <li><strong>Metformin:</strong> Addresses the insulin-driven androgen production.</li>
            <li><strong>Myo-inositol:</strong> Works alongside Metformin to improve the LH/FSH ratio (often 3:1 in PCOS) toward a healthier 1:1.</li>
            <li><strong>Methylated B-Complex:</strong> Counteracts Metformin's B-depletion and fuels COMT.</li>
        </ul>

        <h2 id="section6">6. Individualized Care: Cycle Syncing</h2>
        <p>We must <strong>Individualize Care</strong> (Module 3) by teaching clients to work <i>with</i> their physiology rather than against it. Hormonal detoxification needs change throughout the month.</p>

        <div class="principle-card">
            <div class="principle-title">Follicular Phase (Days 1-14)</div>
            <div class="principle-text">
                Focus on <strong>Estrogen Metabolism</strong>. This is the time for high-intensity cruciferous intake (broccoli sprouts, kale) to prime the CYP1A1 pathway. 
                <ul>
                    <li>Nutrient focus: Zinc and Vitamin A for follicle development.</li>
                    <li>Exercise: Higher intensity (metabolic conditioning) to improve insulin sensitivity.</li>
                </ul>
            </div>
        </div>

        <div class="principle-card">
            <div class="principle-title">Luteal Phase (Days 15-28)</div>
            <div class="principle-text">
                Focus on <strong>Progesterone Support & Clearance</strong>. As progesterone rises, we need to ensure the liver isn't overwhelmed by the prior estrogen peak.
                <ul>
                    <li>Nutrient focus: Magnesium and Vitamin B6 (essential for the corpus luteum).</li>
                    <li>Dietary focus: Slow-burning carbohydrates (sweet potato, squash) to prevent the progesterone-related "sugar crash."</li>
                </ul>
            </div>
        </div>

        <div class="check-understanding">
            <p class="box-label">Check Your Understanding</p>
            <p class="box-subtitle">Test your clinical reasoning on advanced hormonal detoxification.</p>
            
            <div class="question-item">
                <p class="question-text">1. Why might a patient with a "Slow" COMT genotype experience worse symptoms of estrogen dominance when they start a high-dose Phase I inducer like DIM without Phase II support?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">
                    DIM increases the production of hydroxy-estrogens (Phase I). If the COMT enzyme (Phase II) is slow or lacks methyl donors, these metabolites (especially 4-OH) can accumulate, potentially causing more oxidative stress and DNA damage before they can be neutralized. Always ensure methylation support (B12, Folate, Magnesium) is in place.
                </div>
            </div>

            <div class="question-item">
                <p class="question-text">2. What is the primary role of Calcium D-Glucarate in the Estrobolome?</p>
                <button class="reveal-btn" onclick="this.nextElementSibling.classList.toggle('show')">Reveal Answer</button>
                <div class="answer-text">
                    It inhibits the enzyme beta-glucuronidase produced by certain gut bacteria. This prevents the "de-conjugation" of estrogen, ensuring that the estrogen packaged by the liver actually leaves the body in the stool rather than being reabsorbed.
                </div>
            </div>
        </div>

        <div class="takeaways-box">
            <p class="box-label">Key Takeaways</p>
            <ul>
                <li>PCOS is a multi-systemic disorder involving insulin, androgens, and impaired estrogen clearance.</li>
                <li>Phase II detoxification (Methylation) is often the "hidden bottleneck" in refractory hormonal cases.</li>
                <li>The Estrobolome acts as a "second liver," and high beta-glucuronidase can negate hepatic detox efforts.</li>
                <li>Data-driven decisions using DUTCH and genetic SNPs (COMT/MTHFR) allow for precision supplement dosing.</li>
                <li>Cycle syncing nutrition ensures that the practitioner is supporting the specific metabolic needs of each hormonal phase.</li>
            </ul>
        </div>

        <div class="references-box">
            <h4>References & Further Reading</h4>
            <p>1. Azziz et al. (2019). "The Polycystic Ovary Syndrome." Nature Reviews Disease Primers.</p>
            <p>2. Baker et al. (2017). "The Gut Microbiome: An Underappreciated Factor in Estrogen Homeostasis." Maturitas.</p>
            <p>3. Hall et al. (2022). "COMT Genetic Polymorphism and Its Impact on Estrogen Metabolism in Women." Journal of Clinical Endocrinology & Metabolism.</p>
            <p>4. Teede et al. (2023). "Recommendations from the 2023 International Evidence-based Guideline for the Assessment and Management of PCOS." Fertility and Sterility.</p>
            <p>5. Lord et al. (2021). "The Role of Calcium D-Glucarate in Hormone Excretion: A Clinical Review." Integrative Medicine Journal.</p>
            <p>6. Kwa et al. (2016). "The Intestinal Microbiome and Estrogen Receptor‚ÄìPositive Female Breast Cancer." Journal of the National Cancer Institute.</p>
        </div>

        <footer class="lesson-footer">
            <img src="/logoimg/LOGO_ACCREDI.png" alt="AccrediPro Academy" class="footer-logo">
            <p class="brand">AccrediPro Academy: Integrative Medicine Practitioner Certification</p>
            <p class="copyright">&copy; 2024 AccrediPro. All rights reserved. Professional Use Only.</p>
        </footer>
    </div>
</body>

</html>